HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia.

AuthorsFotini Vogiatzi, Dorothee Winterberg, Lennart Lenk, Swantje Buchmann, Gunnar Cario, Martin Schrappe, Matthias Peipp, Paulina Richter-Pechanska, Andreas E Kulozik, Jana Lentes, Anke K Bergmann, Thomas Valerius, Fabian-Simon Frielitz, Christian Kellner, Denis M Schewe
JournalBlood (Blood) Vol. 134 Issue 8 Pg. 713-716 (08 22 2019) ISSN: 1528-0020 [Electronic] United States
PMID31311816 (Publication Type: Letter, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • daratumumab
Topics
  • Adolescent
  • Antibodies, Monoclonal (therapeutic use)
  • Antineoplastic Agents (therapeutic use)
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Male
  • Neoplasm, Residual (drug therapy)
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (drug therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: